TY - JOUR
T1 - Effectiveness of antiangiogenic drugs in glioblastoma patients
T2 - A systematic review and meta-analysis of randomized clinical trials
AU - Lombardi, Giuseppe
AU - Pambuku, Ardi
AU - Bellu, Luisa
AU - Farina, Miriam
AU - Della Puppa, Alessandro
AU - Denaro, Luca
AU - Zagonel, Vittorina
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Background glioblastomas are highly vascularized tumors and various antiangiogenic drugs have been investigated in clinical trials showing unclear results. We performed a systematic review and a meta-analysis to clarify and evaluate their effectiveness in glioblastoma patients. Patients and methods we searched relevant published and unpublished randomized clinical trials analyzing antiangiogenic drugs versus chemotherapy in glioblastoma patients from January 2006 to January 2016 in MEDLINE, WEB of SCIENCE, ASCO, ESMO and SNO databases. Results fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients. Antiangiogenic drugs showed no improvement in overall survival with a pooled HR of 1.00, a trend for an inferior outcome, in terms of overall survival, was observed in the group of patients receiving antiangiogenic drug alone compared to cytotoxic drug alone (HR = 1.24, p = 0.056). Bevacizumab did not improve overall survival. Twelve trials (4113 patients) were analyzed for progression-free survival. Among antiangiogenic drugs, only bevacizumab demonstrated an improvement of progression-free survival (HR = 0.63, p < 0.001), both alone (HR = 0.60, p = 0.003) or in combination to chemotherapy (HR = 0.63; p < 0.001), both as first-line treatment (HR = 0.70, p < 0.001) or in recurrent disease (HR = 0.52, p < 0.001). Conclusions antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy. Among antiangiogenic drugs, only bevacizumab improved progression-free survival regardless of treatment line, both as single agent or in combination with chemotherapy
AB - Background glioblastomas are highly vascularized tumors and various antiangiogenic drugs have been investigated in clinical trials showing unclear results. We performed a systematic review and a meta-analysis to clarify and evaluate their effectiveness in glioblastoma patients. Patients and methods we searched relevant published and unpublished randomized clinical trials analyzing antiangiogenic drugs versus chemotherapy in glioblastoma patients from January 2006 to January 2016 in MEDLINE, WEB of SCIENCE, ASCO, ESMO and SNO databases. Results fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients. Antiangiogenic drugs showed no improvement in overall survival with a pooled HR of 1.00, a trend for an inferior outcome, in terms of overall survival, was observed in the group of patients receiving antiangiogenic drug alone compared to cytotoxic drug alone (HR = 1.24, p = 0.056). Bevacizumab did not improve overall survival. Twelve trials (4113 patients) were analyzed for progression-free survival. Among antiangiogenic drugs, only bevacizumab demonstrated an improvement of progression-free survival (HR = 0.63, p < 0.001), both alone (HR = 0.60, p = 0.003) or in combination to chemotherapy (HR = 0.63; p < 0.001), both as first-line treatment (HR = 0.70, p < 0.001) or in recurrent disease (HR = 0.52, p < 0.001). Conclusions antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy. Among antiangiogenic drugs, only bevacizumab improved progression-free survival regardless of treatment line, both as single agent or in combination with chemotherapy
KW - Antiangiogenic drugs
KW - Bevacizumab
KW - Chemotherapy
KW - Glioblastoma
UR - http://www.scopus.com/inward/record.url?scp=85014072446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014072446&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2017.01.018
DO - 10.1016/j.critrevonc.2017.01.018
M3 - Review article
C2 - 28259301
AN - SCOPUS:85014072446
VL - 111
SP - 94
EP - 102
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -